| abstract |
Disclosed are methods for the detection of HER-2 in a biological sample using mass spectrometry. Specifically, these methods detect a cysteine-free HER-2 fragment peptide in the biological sample. The presence of HER-2 in a biological sample can be used to determine if a subject has a HER-2 associated cancer. The presence of HER-2 associated cancer can be used to determine if a subject would benefit from a HER-2 targeted therapy, such as an anti-HER-2 antibody. In one aspect, these methods can be used to quantify HER-2 in a biological sample via mass spectrometry by using an optionally isotopically labeled peptide standard. |